Matches in SemOpenAlex for { <https://semopenalex.org/work/W2508288722> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2508288722 endingPage "5111" @default.
- W2508288722 startingPage "5111" @default.
- W2508288722 abstract "5111 Background: Treatment of recurrent or persistent epithelial ovarian cancer (EOC) is mainly palliative and therefore quality of life is of high priority. This study purpose is to evaluate the safety as well as response rate, time to progression and survival of Topotecan in the weekly schedule for recurrent and persistent epithelial ovarian cancer and primary peritoneal cancer. Methods: Seventeen EOC patients with recurrent or persistent disease, previously exposed to not more than one platinum-based regimen (mostly carboplatin and paclitaxel) were treated with weekly Topotecan. Topotecan at a dose of 4 mg/m2 was administered on days 1,8 and 15 every 28-days cycle. Results: The median age of the study group was 59 years (42–75). A median ECOG performance status of 1 (0–2). Six (35%) patients had a persistent disease on carboplatin and paclitaxel. Nine women had a platinum sensitive disease and 8 platinum resistant. Patients were exposed to a median of 5(2–6) cycles of weekly Topotecan. With a median follow up of 12(1.2–18.93) months. Five (29.4%) complete responses (CR) were observed, 2(11.8%) partial responses (PR) and 7(41.1%) stable disease (SD) with an overall response rate of 41.2%. Of the CR’s patients, 2 are still in remission after 12 and 4 months, three recur after 2,3 and 6 months. Median time to progression (TTP) is 6.87 months (1.2–16), 3 of the CR’s had persistent disease, one CR was Ic and one IIc. The median overall survival time is 12+ months (1.2–18.93) with all but one patient alive. Bone marrow toxicity consisted of 1(5.8%) patient with grade III thrombocytopenia followed by treatment cessation, 2(11.8%) patients with grade II anemia and 1(5.8%) grade II neutropenia. Non-hematologic toxicity consisted of mild alopecia, nausea and fatigue. Grade I fatigue was noted in 4 (23.5%) patients and grade III in 1(5.8%) and 2 (11.8%) patients had grade I nausea. Grade II-III toxicities were rare and no treatment delays was needed. Conclusions: Topotecan given, as a weekly bolus is an active and well-tolerated first-line regimen for persistent and relapsed ovarian cancer. It seems to be less toxic compared to the 5-day schedule and warrants further investigation. No significant financial relationships to disclose." @default.
- W2508288722 created "2016-09-16" @default.
- W2508288722 creator A5026530180 @default.
- W2508288722 creator A5027233973 @default.
- W2508288722 creator A5039578268 @default.
- W2508288722 creator A5041214836 @default.
- W2508288722 creator A5041578969 @default.
- W2508288722 creator A5061136502 @default.
- W2508288722 creator A5073763150 @default.
- W2508288722 creator A5091241832 @default.
- W2508288722 date "2005-06-01" @default.
- W2508288722 modified "2023-10-11" @default.
- W2508288722 title "Weekly topotecan as first-line treatment for recurrent or persistent epithelial ovarian cancer (EOC)" @default.
- W2508288722 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.5111" @default.
- W2508288722 hasPublicationYear "2005" @default.
- W2508288722 type Work @default.
- W2508288722 sameAs 2508288722 @default.
- W2508288722 citedByCount "0" @default.
- W2508288722 crossrefType "journal-article" @default.
- W2508288722 hasAuthorship W2508288722A5026530180 @default.
- W2508288722 hasAuthorship W2508288722A5027233973 @default.
- W2508288722 hasAuthorship W2508288722A5039578268 @default.
- W2508288722 hasAuthorship W2508288722A5041214836 @default.
- W2508288722 hasAuthorship W2508288722A5041578969 @default.
- W2508288722 hasAuthorship W2508288722A5061136502 @default.
- W2508288722 hasAuthorship W2508288722A5073763150 @default.
- W2508288722 hasAuthorship W2508288722A5091241832 @default.
- W2508288722 hasConcept C121608353 @default.
- W2508288722 hasConcept C126322002 @default.
- W2508288722 hasConcept C141071460 @default.
- W2508288722 hasConcept C143998085 @default.
- W2508288722 hasConcept C2776694085 @default.
- W2508288722 hasConcept C2777292972 @default.
- W2508288722 hasConcept C2778239845 @default.
- W2508288722 hasConcept C2778822529 @default.
- W2508288722 hasConcept C2780427987 @default.
- W2508288722 hasConcept C2781209748 @default.
- W2508288722 hasConcept C2781413609 @default.
- W2508288722 hasConcept C2781451048 @default.
- W2508288722 hasConcept C2992773878 @default.
- W2508288722 hasConcept C71924100 @default.
- W2508288722 hasConcept C90924648 @default.
- W2508288722 hasConceptScore W2508288722C121608353 @default.
- W2508288722 hasConceptScore W2508288722C126322002 @default.
- W2508288722 hasConceptScore W2508288722C141071460 @default.
- W2508288722 hasConceptScore W2508288722C143998085 @default.
- W2508288722 hasConceptScore W2508288722C2776694085 @default.
- W2508288722 hasConceptScore W2508288722C2777292972 @default.
- W2508288722 hasConceptScore W2508288722C2778239845 @default.
- W2508288722 hasConceptScore W2508288722C2778822529 @default.
- W2508288722 hasConceptScore W2508288722C2780427987 @default.
- W2508288722 hasConceptScore W2508288722C2781209748 @default.
- W2508288722 hasConceptScore W2508288722C2781413609 @default.
- W2508288722 hasConceptScore W2508288722C2781451048 @default.
- W2508288722 hasConceptScore W2508288722C2992773878 @default.
- W2508288722 hasConceptScore W2508288722C71924100 @default.
- W2508288722 hasConceptScore W2508288722C90924648 @default.
- W2508288722 hasIssue "16_suppl" @default.
- W2508288722 hasLocation W25082887221 @default.
- W2508288722 hasOpenAccess W2508288722 @default.
- W2508288722 hasPrimaryLocation W25082887221 @default.
- W2508288722 hasRelatedWork W1967715255 @default.
- W2508288722 hasRelatedWork W2003230459 @default.
- W2508288722 hasRelatedWork W2024576940 @default.
- W2508288722 hasRelatedWork W2071238546 @default.
- W2508288722 hasRelatedWork W2092909014 @default.
- W2508288722 hasRelatedWork W2289428780 @default.
- W2508288722 hasRelatedWork W2311734504 @default.
- W2508288722 hasRelatedWork W2320097775 @default.
- W2508288722 hasRelatedWork W24553618 @default.
- W2508288722 hasRelatedWork W2466209479 @default.
- W2508288722 hasVolume "23" @default.
- W2508288722 isParatext "false" @default.
- W2508288722 isRetracted "false" @default.
- W2508288722 magId "2508288722" @default.
- W2508288722 workType "article" @default.